Integrated psychiatric management of Prader-Willi syndrome: a case report of disruptive mood dysregulation and ADHD

Parinda Parikh; Alisha A. Alphonse; Himani J. Suthar; Shaurya K. Singh; Amanjot Singh; Mina Oza

doi:10.18203/2394-6040.ijcmph20252144

Authors

Parinda Parikh Department of Psychiatry, Weill Cornell Medical School, White Plains, New York, USA
Alisha A. Alphonse St. George’s University, Grenada
Himani J. Suthar GMERS Medical College and Civil Hospital, Gandhinagar, India
Shaurya K. Singh Pravara Institute of Medical Sciences, Loni, Maharashtra, India
Amanjot Singh Maharaja Agrasen Medical College, Agroha, India
Mina Oza 2nd ARC Associates, White Plains, NY, USA

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20252144

Keywords:

Aggression, ADHD, Disruptive Behaviours, Prader-Willi-Syndrome

Abstract

Prader-Willi syndrome (PWS) is a genetic disorder characterized by behavioral disturbances such as temper outbursts, impulsivity, aggression, and self-injury. Due to symptom overlap, psychiatric comorbidities including ADHD, obsessive-compulsive behaviors, and disruptive mood disorders are frequently underdiagnosed. These symptoms typically emerge early in life and persist into adulthood, contributing to caregiver burden and functional impairment. Neuroimaging studies reveal abnormalities in brain regions associated with emotional regulation and social behavior, while epigenetic research points to altered methylation patterns in genes which may contribute to behavioral dysregulation. Despite the significant impact of these symptoms, pharmacological management lacks standardization and relies largely on case-based evidence, highlighting the need for detailed clinical documentation to guide individualized care. A 19-year-old male with PWS presented with food preoccupation, anxiety, mood swings, social challenges, and aggression. Multiple failed medication preceded the eventual diagnosis of disruptive mood dysregulation disorder (DMDD) and ADHD. A revised treatment plan led to marked clinical improvement in emotional regulation and functioning. This case illustrates the complexity of diagnosing and treating psychiatric comorbidities in PWS, where overlapping symptoms can obscure accurate assessment and delay appropriate intervention. The absence of standardized guidelines and limited empirical data reflect a critical need for focused research to refine diagnostic criteria and develop effective, evidence-based therapies. Greater understanding of the psychiatric profile of PWS is essential for improving outcomes and quality of life in this vulnerable population.

Metrics

Metrics Loading ...

References

Emerick JE, Vogt KS. Endocrine manifestations and management of Prader-Willi syndrome. Int J Pediatr Endocrinol. 2013;2013(1):14. DOI: https://doi.org/10.1186/1687-9856-2013-14

Steinhausen HC, Eiholzer U, Hauffa BP, Malin Z. Behavioural and emotional disturbances in people with Prader-Willi Syndrome. J Intellect Disabil Res. 2004;48(1):47–52. DOI: https://doi.org/10.1111/j.1365-2788.2004.00582.x

Rice LJ, Woodcock K, Einfeld SL. The characteristics of temper outbursts in Prader-Willi syndrome. Am J Med Genet A.2018;176(11):2292–300. DOI: https://doi.org/10.1002/ajmg.a.40480

Shriki-Tal L, Avrahamy H, Pollak Y, Gross-Tsur V, Genstil L, Hirsch HJ, et al. Psychiatric disorders in a cohort of individuals with Prader–Willi syndrome. Eur Psychiatry. 2017;44:47–52. DOI: https://doi.org/10.1016/j.eurpsy.2017.03.007

Stein DJ, Keating J, Zar HJ, Hollander E. A survey of the phenomenology and pharmacotherapy of compulsive and impulsive-aggressive symptoms in Prader-Willi syndrome. J Neuropsychiatry Clin Neurosci. 1994;6(1):23–9. DOI: https://doi.org/10.1176/jnp.6.1.23

Bonnot O, Cohen D, Thuilleaux D, Consoli A, Cabal S, Tauber M. Psychotropic treatments in Prader-Willi syndrome: A critical review of published literature. Eur J Pediatr. 2016;175(1):9–18. DOI: https://doi.org/10.1007/s00431-015-2670-x

Arron K, Oliver C, Moss J, Berg K, Burbidge C. The prevalence and phenomenology of self-injurious and aggressive behaviour in genetic syndromes. J Intellect Disabil Res. 2011;55(2):109–20. DOI: https://doi.org/10.1111/j.1365-2788.2010.01337.x

Mantoulan C, Payoux P, Diene G, Glattard M, Rogé B, Molinas C, et al. PET scan perfusion imaging in the Prader-Willi syndrome: New insights into the psychiatric and social disturbances. Behav Brain Res. 2011;217(1):3–28. DOI: https://doi.org/10.1038/jcbfm.2010.87

Deest M, Jakob MM, Seifert J, Bleich S, Frieling H, Eberlein CK. Sertraline as a treatment option for temper outbursts in Prader-Willi syndrome. Orphanet J Rare Dis. 2021;16:34. DOI: https://doi.org/10.1186/s13023-022-02470-y

Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J. Risperidone in treating behavioural disturbances of Prader-Willi syndrome. Acta Psychiatr Scand. 2000;102(6):461–5. DOI: https://doi.org/10.1034/j.1600-0447.2000.102006461.x

Akça ÖF, Yilmaz S. Aripiprazole in the treatment of obsessive-compulsive disorder and aggressive behaviors in a child with Prader-Willi syndrome: A case report. J Clin Psychopharmacol. 2016;36(5):526–8. DOI: https://doi.org/10.1097/JCP.0000000000000566

Singh D, Wakimoto Y, Filangieri C, Pinkhasov A, Angulo M. Guanfacine extended release for the reduction of aggression, attention-deficit/hyperactivity disorder symptoms, and self-injurious behavior in Prader-Willi syndrome—A retrospective cohort study. J Child Adolesc Psychopharmacol. 2019;29(10):753–9. DOI: https://doi.org/10.1089/cap.2018.0102

Singh D, Silver M, Jacob T. A randomized double-blind placebo-controlled trial of Guanfacine Extended Release for aggression and self-injurious behavior associated with Prader-Willi Syndrome. medRxiv; 2024. doi:10.1101/2024.08.22.24312419. DOI: https://doi.org/10.1101/2024.08.22.24312419

Consoli A, Bodeau N, Cabal S, Evrard C, Wachtel L, Cohen D, et al. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study. Orphanet J Rare Dis. 2019;14(1):273. DOI: https://doi.org/10.1038/s41398-019-0597-0

Benjamin E, Buot-Smith T. Naltrexone and fluoxetine in Prader-Willi syndrome. Am J Med Genet. 1993;47(5):739–41. DOI: https://doi.org/10.1097/00004583-199307000-00025

Warnock JK, Kestenbaum T. Pharmacologic treatment of severe skin-picking behaviors in Prader-Willi syndrome. Two case reports. Arch Dermatol. 1992;128(11):1618–9. DOI: https://doi.org/10.1001/archderm.1992.04530010061009

Tauber M, Mantoulan C, Copet P, Jauregui J, Demeer G, Diene G, et al. Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: A randomised placebo-controlled trial in 24 patients. Orphanet J Rare Dis. 2011;6:47. DOI: https://doi.org/10.1186/1750-1172-6-47

Holland AJ, Aman LCS, Whittington JE. Defining mental and behavioural disorders in genetically determined neurodevelopmental syndromes with particular reference to Prader-Willi syndrome. Genes (Basel). 2019;10(12):1025. DOI: https://doi.org/10.3390/genes10121025